Real Life Use of Alemtuzumab, Cladribine, Dimethylfumarate, Fingolimod, Natalizumab, Ocrelizumab and Teriflunomide in Austria: Benefit-Risk Data from the Austrian Multiple Sclerosis Treatment Registry

  • Michael Guger (Speaker)

Activity: Talk or presentation › Poster presentation › science-to-science

Period20 Sept 2020
Event titleunbekannt/unknown
Event typeConference
LocationAustriaShow on map

Fields of science

  • 305 Other Human Medicine, Health Sciences
  • 304 Medical Biotechnology
  • 303 Health Sciences
  • 302 Clinical Medicine
  • 301 Medical-Theoretical Sciences, Pharmacy